Recon: CVS won’t add Gilead’s HIV PREP jab to coverage lists; J&J to make $2B investment in US drug manufacturing

• Trump may push hard for lower drug prices using a tool created by Democrats (STAT)
• US FDA approves Ionis' drug for rare genetic disorder (Reuters)
• FDA agrees to speed review for an ultra-rare disease drug (STAT)
• Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists (Reuters)
• J&J to invest $2 billion to boost US manufacturing as drug tariffs loom (Reuters)
• Politicizing Scientific Research Comes With a Hefty Price (Bloomberg)
• HHS, CMS form advisory committee to improve patient care, call for nominations (Reuters)
• FDA’s new expert panels are rife with financial conflicts and fringe views (LA Times)

• Japan's Takeda weighs India for global trials to speed up drug launches (Reuters)
• Trump’s ‘most favored nation’ policy will apply to EU generics (Endpoints)
• Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades (Bloomberg)
• Novo Obesity Shot Sees Interest Soar in UK as Rival Lifts Prices (Bloomberg)
• US, EU agree to terms of framework trade pact (MedTech Dive)

• Sarepta extends $700M debt to 2030, adds private placement amid Elevidys uncertainty (Fierce Pharma)
• As Sarepta Therapeutics fights for Duchenne therapy, a group of patients gets left behind (STAT)
• FDA ‘uncertainty’ forces Krystal Biotech to shutter cancer drug trial (STAT)
• Serena Williams to promote weight-loss drugs with telehealth firm Ro (Reuters)
• Riding high on Wegovy, Novo doubled its workforce. Now layoffs loom (Reuters)
• Gilead unit to acquire cell therapy developer Interius for $350 million (Reuters)
• Prader-Willi syndrome is not a zero-sum game. There's room for many winners (Endpoints)
• Nicox eyes FDA submission as ocular hypertension drug passes Phase 3 (Endpoints)
• Dynavax says its shingles shot was 'comparable' to Shingrix in early readout (Endpoints)
• Rezolute hires ex-Ultragenyx exec for rare disease launch (Fierce Pharma)
• Swoop, iSpot team up to tackle TV ad transparency for pharma (Fierce Pharma)

• FDA approves first-ever glucose monitoring system for weight loss from Signos (CNBC)
• Epic’s AI overhaul promises to address EHR headaches for clinicians and patients (STAT)
• AdvaMed urges Dr. Oz to speed Medicare coverage of breakthrough devices (MedTech Dive)
• More than 1,100 devices have received the FDA’s breakthrough designation (MedTech Dive)
• Hip Resurfacing For Women: Embody Orthopaedic Awarded CE Mark For H1 Implant (MedTech Insight)

• The Infant Food Revolution: Whole Foods Before Teeth (Bloomberg)
• Trump administration to explore limits on advertising unhealthy foods to kids (Food Dive)

• How Deeply Trump Has Cut Federal Health Agencies (ProPublica)
• What updated thresholds for statin use could mean for patients (STAT)
• Congress must continue to support the VA’s research into psychedelics for PTSD (STAT)
• Masimo sues US Customs over approval of Apple Watch imports (Reuters)
• Healthcare costs to go up 9% in 2026 for large employers (Endpoints)